Gout Management Guidelines

Acute Gout Treatment

The American College of Physicians recommends first-line treatments for acute gout attacks, including corticosteroids, NSAIDs, or colchicine, which should be initiated within 24 hours of symptom onset for optimal outcomes 1, 2
Corticosteroids are considered first-line therapy in patients without contraindications due to their safety profile and low cost, with prednisolone 35 mg daily for 5 days being effective for acute gout 1, 3
NSAIDs should be used at full FDA-approved anti-inflammatory/analgesic doses, with FDA-approved NSAIDs for acute gout including naproxen, indomethacin, and sulindac 4, 5
Colchicine is effective when started within 36 hours of symptom onset, with a low-dose regimen of 1.2 mg followed by 0.6 mg 1 hour later being as effective as higher doses with fewer gastrointestinal side effects 4, 6

Prophylaxis is strongly recommended when starting urate-lowering therapy to prevent flares, and prophylactic therapy should be continued for more than 8 weeks when initiating urate-lowering therapy 1, 2
Colchicine is a first-line option for gout attack prophylaxis, with a dosage of 0.6 mg once or twice daily (maximum 1.2 mg/day) 7, 2
Low-dose NSAIDs are an appropriate choice for first-line gout attack prophylaxis if colchicine is not tolerated 1, 2

Urate-lowering therapy is not recommended after a first gout attack or in patients with infrequent attacks, but is indicated for patients with recurrent acute attacks (≥2 per year), tophi, or radiographic changes of gout 1, 2, 8
Xanthine oxidase inhibitors, such as allopurinol or febuxostat, are first-line options for urate-lowering therapy 1, 2
The target serum urate level should be below 6 mg/dL 2

Initiating treatment within 24 hours of symptom onset provides the best results 5, 2
Patient-specific factors, such as renal impairment, diabetes, cardiovascular disease, and gastrointestinal risk factors, should be considered when selecting treatment options 3, 8
Common pitfalls, such as high-dose colchicine regimens, discontinuing urate-lowering therapy during acute flares, and inadequate duration of prophylaxis, can worsen outcomes 2, 5, 1